Pooled analysis of CNS response to alectinib in two phase 2 studies of pre-treat
PUBLISHED: 2015-11-26  778 total views, 1 today

Sai-hong Ou1, Alice Shaw1, Ramaswamy Govindan1, Mark Socinski1Ross Camidge1, Luigi De Petris2,Dong-wan Kim3, Alberto Chiappori1Denis Moro-sibilot4,Michael Duruisseaux4, Lucio Crino5, Tommaso De Pas5Eric Dansin4, Antje Tessmer6,James Yang7, Ji-youn Han3, Walter Bordogna8Sophie Golding8, Ali Zeaiter8, Shirish Gadgeel1

1Medicine-Hematology/Oncology,Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine,USA, 2Sweden, 3South Korea, 4France,5Italy, 6Germany, 7Taiwan, 8Roche


Objective:The central nervous system (CNS) is afrequent site of progression in ALK+ NSCLC patients treated withcrizotinib, thus good CNS efficacy is of crucial importance for new ALKinhibitors. Two recent phase II studies examined the efficacy and safety ofalectinib in patients with ALK+ NSCLC who progressed after crizotinib;data from both studies were pooled to further examine the efficacy of alectinibin the CNS. Method: Both phase II, single-arm, multicenter studiesenrolled ALK+ NSCLC patients previously treated with crizotinib. Onestudy was conducted in North America only (NP28761; NCT01871805), the other wasglobal (NP28673; NCT01801111). All patients received 600mg oral alectinib twicedaily. A primary endpoint of both studies was objective response rate (ORR) byindependent review committee (IRC) and key secondary endpoints included CNS ORRby IRC and CNS duration of response (DOR). Response was determined according toRECIST v1.1. All patients underwent imaging at baseline to assess CNSmetastases. Result: The pooled analysis population comprised 225patients (n=87 from NP28761 and n=138 from NP28673); baseline characteristicswere similar to each study population, with most patients being non-smokers,(MD) while a further 85 had non-measurable disease (NMD) at baseline; bothgroups together (M+NMD) comprised 135 patients, 60% of the overall studypopulation. In the MD group, 34 patients (68%) had received prior radiotherapy,but 24 of them had completed that radiotherapy >6 months prior to startingalectinib. For the M+NMD group, 94 patients (70%) had received prior radiotherapy,with 55 completing this >6 months prior to starting alectinib. In the MDgroup, 30/50 patients had a CNS response (60.0%; 95% CI 45.2–73.6%), with 7complete responses (CR; 14.0%) and a CNS DCR of 90.0% (78.2–96.7%). In theM+NMD group, 22 additional patients had a CR (29/135; 21.5%), giving a CNS ORRof 38.5% (30.3–47.3%), with a CNS DCR of 85.2% (78.1-90.7%). Complete responseswere seen in patients with and without prior radiotherapy. Median CNS DOR afteronly 17% of events in both groups was 7.6 months (5.8–7.6) in the MD group(n=30) and 7.6 months (5.8-10.3) in the M+NMD group (n=52), which is similar tothe systemic DOR reported in both studies (Ou et al, ASCO 2015; Gandhi et al, ASCO2015). Tolerability was also similar to the overall study population. Conclusion:Alectinib showed promising efficacy in the CNS in ALK+ NSCLCpatients previously treated with crizotinib, achieving a complete response rateof 22% and a DCR of 85%, irrespective of prior radiotherapy. The CNS responsewas sustained for an equivalent duration to the systemic response, suggestingthat alectinib could provide an effective treatment for patients with ALK+ NSCLC while actively targetingCNS metastases. The ongoing phase III clinical studies will assess the systemicand CNS efficacy of alectinib versus crizotinib as front-line therapy for ALK+ NSCLC patients.


Key Words: alectinib  CNS metastasis  ALK positive non-small cell

Copyright © 1998 - 2019 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us



Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)